Notice of NCI Participation in RFA-AI-18-054, U.S.-Brazil Collaborative Biomedical Research Program (R01 Clinical Trial Optional)

Notice Number: NOT-CA-19-014

Key Dates
Release Date: December 19, 2018

Related Announcements

Issued by
National Cancer Institute (NCI)


The purpose of this Notice is to inform potential applicants that the National Cancer Institute (NCI) is participating, effective immediately, in RFA-AI-18-054, U.S.-Brazil Collaborative Biomedical Research Program (R01 Clinical Trial Optional).

The following changes have been made in RFA-AI-18-054 under each of the headings (below) to reflect NCI's participation in this funding opportunity announcement (FOA):

Part 1. Overview Information

Components of Participating Organizations

National Cancer Institute (NCI)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.393, 93.394, 93.395, 93.396, 93.399

Part 2. Section I. Funding Opportunity Description

[Text below is inserted near the end of this section just after the end of the subsection entitled "Environmental Health Sciences" and just before the start of the statement "The following applications will be considered non-responsive and will not be reviewed. ]

Cancer (not HIV/AIDS-related)

  • Basic research in cancer biology.
  • Research in cancer surveillance, epidemiology, health services, behavioral science, and cancer survivorship.
  • Research to assess a person's risk of developing cancer and to find ways to reduce that risk.
  • Initial small-scale testing of new anticancer agents, biomarkers, imaging tests, and other therapeutic interventions.
  • Research to identify new and innovative scientific opportunities to improve cancer outcomes in communities experiencing an excess burden of cancer.
  • Exploratory programs to develop advanced technologies, trans-disciplinary approaches, infrastructures, and standards to accelerate the creation of publicly available data, knowledge, and tools for cancer research.

HIV-Associated Malignancies

  • Epidemiology of HIV-associated cancers in the era of antiretroviral therapy, including evaluation of risk factors (e.g., tobacco, alcohol, drugs, infections, diet, and nutrition) that impact cancer in the context of HIV infection in Brazil.
  • Identification of biological differences between AIDS-defining and non-AIDS-defining tumors, including differences in tumor sequences and gene expression of tumors.
  • Determination of pathogenic or immunological mechanisms involved in the interactions between HIV, other opportunistic infections and oncogenic viruses such as human papilloma virus (HPV), human herpes virus (EBC and HHV-8), and Hepatitis B and C virus, which lead to increased risk or the development of cancer.
  • Understanding the pathogenesis and pathobiology of HIV-associated cancers (AIDS-defining and non-AIDS-defining), including the role of long-term antiretroviral therapy.
  • Optimization of the diagnosis, prevention, and treatment of HIV-associated cancers, including the development of biomarkers for early detection, progression or response to treatment of HIV-associated cancers.
  • Comparison of complications and outcomes of treatment of cancers in HIV-infected populations versus non-infected populations.
  • Improvement of clinical outcomes by integrating screening services for cancer (e.g., screening for cervical and anal cancer) and HIV treatment.

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)

Paul C. Pearlman, Ph.D.
National Cancer Institute
Telephone: 240-276-5354

Financial/Grants Management Contact(s)

Crystal Wolfrey
National Cancer Institute
Telephone: 240-276-6277

All other aspects of this FOA remain unchanged.


Please direct all inquiries to:

Paul C. Pearlman, Ph.D.
National Cancer Institute
Telephone: 240-276-5354